MyFinsight
Home
About
Contact
chrs: the income statement
Download
Download image
Net revenue
$10,663K
Income from operations
$9,486K
Total costs and
expenses
$1,177K
Net income (loss)
from discontinued...
$8,986K
Other income
(expense), net
-$78K
Gain on sale
transactions, net
-$422K
Selling, general and
administrative
$326K
Research and development
$564K
Cost of goods sold
$287K
Net income (loss)
-$35,531K
(-230.49%↓ Y/Y)
Net income from
discontinued operations, net...
$8,986K
Net loss from
continuing operations
-$44,517K
Loss from continuing
operations before income...
-$44,517K
(-314.07%↓ Y/Y)
Other income
(expense), net
$2,141K
(2.74%↑ Y/Y)
Product And Service
Other
$402K
Toripalimab
$11,169K
Interest expense
$2,325K
(-56.64%↓ Y/Y)
Loss from operations
-$44,333K
(-594.11%↓ Y/Y)
Net revenue
$11,571K
(-83.65%↓ Y/Y)
Total costs and
expenses
$55,904K
(-27.55%↓ Y/Y)
Selling, general and
administrative
$24,931K
(-28.24%↓ Y/Y)
Research and development
$27,252K
(25.72%↑ Y/Y)
Cost of goods sold
$3,721K
(-82.06%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)